WO1999056698A3 - Treatment of celiac disease - Google Patents

Treatment of celiac disease Download PDF

Info

Publication number
WO1999056698A3
WO1999056698A3 PCT/DK1999/000255 DK9900255W WO9956698A3 WO 1999056698 A3 WO1999056698 A3 WO 1999056698A3 DK 9900255 W DK9900255 W DK 9900255W WO 9956698 A3 WO9956698 A3 WO 9956698A3
Authority
WO
WIPO (PCT)
Prior art keywords
interfering
deamidation
celiac disease
glutamine residue
gliadin
Prior art date
Application number
PCT/DK1999/000255
Other languages
French (fr)
Other versions
WO1999056698A2 (en
Inventor
Hans Sjoestroem
Ove Noren
Original Assignee
Univ Koebenhavn
Hans Sjoestroem
Ove Noren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Koebenhavn, Hans Sjoestroem, Ove Noren filed Critical Univ Koebenhavn
Priority to AU35961/99A priority Critical patent/AU3596199A/en
Priority to EP99917810A priority patent/EP1075267A2/en
Publication of WO1999056698A2 publication Critical patent/WO1999056698A2/en
Publication of WO1999056698A3 publication Critical patent/WO1999056698A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a method of treating celiac disease comprising interfering with the deamidation of at least one glutamine residue in a gliadin or glutenin molecule. This may be provided by prohibiting or interfering with the deamidation of at least one glutamine residue by derivation of at least one glutamine residue in a gliadin or glutenine molecule in wheat flour by a chemical or enzymatic deamidation of gluten followed by chemical or enzymatic derivation of the generated carboxyl group(s). In a further aspect, the invention relates to a method of interfering with the deamidation of at least one glutamine residue in a gliadin or glutenin molecule and thereby treating celiac disease, the method comprising administering, to a patient having or suspected of having celiac disease, at least one of the following substances: (a) a substance which is capable of increasing the pH in the gastroduodenal tract of a subject, e.g. an antacidum, an anticholinergic agent, H2-receptor antagonists or a proton pump inhibitor, (b) a substance which is capable of eliminating deamidating bacteria in the gastroduodenal tract of a subject, e.g. an antibiotic or antimicrobial agent, and/or (c) a substance which is capable of interfering with the effect of at least one deamidating enzyme in the gastroduodenal tract of a subject.
PCT/DK1999/000255 1998-05-06 1999-05-06 Treatment of celiac disease WO1999056698A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU35961/99A AU3596199A (en) 1998-05-06 1999-05-06 Treatment of celiac disease
EP99917810A EP1075267A2 (en) 1998-05-06 1999-05-06 Treatment of celiac disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK0621/98 1998-05-06
DK62198 1998-05-06
US9154598P 1998-07-01 1998-07-01
US60/091,545 1998-07-01

Publications (2)

Publication Number Publication Date
WO1999056698A2 WO1999056698A2 (en) 1999-11-11
WO1999056698A3 true WO1999056698A3 (en) 1999-12-29

Family

ID=26064330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000255 WO1999056698A2 (en) 1998-05-06 1999-05-06 Treatment of celiac disease

Country Status (3)

Country Link
EP (1) EP1075267A2 (en)
AU (1) AU3596199A (en)
WO (1) WO1999056698A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
PT1191025E (en) 1999-06-30 2005-09-30 Takeda Pharmaceutical LANSOPRAZOL CRYSTALS
DK1572127T4 (en) 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzyme processing of foods for celiac disease
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
CA2771725C (en) 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
CA2502700C (en) * 2002-11-20 2017-01-17 Chaitan Khosla Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
ITMI20062080A1 (en) * 2006-10-30 2008-04-30 Consiglio Nazionale Ricerche TREATMENT OF CEREAL FLOURS FOR FOOD CONSUMPTION BY CELIAC PATIENTS
AU2008229448B2 (en) 2007-03-16 2013-01-24 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
EA017064B1 (en) 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Crystal of benzimidazole compound
JP5937106B2 (en) * 2011-01-20 2016-06-22 サイレックス ラボラトリーズ，エルエルシー Method and apparatus for detecting gluten sensitivity and differentiating gluten sensitivity from celiac disease
WO2012108827A1 (en) * 2011-02-08 2012-08-16 Phadia Ab Wheat antigens and peptides for diagnosis of wheat induced hypersensitivity
ITSR20130002A1 (en) 2013-10-08 2015-04-08 Danilo Ciciulla NEW INDUSTRIAL PROCESS OF PROCESSING FOR THE PRODUCTION OF FARINACEOUS FOODS, INTENDED FOR SUBJECTS WITH CELIAC DISEASE CLINICALLY MANIFESTED, BASED ON COMMON FLOURS.
WO2017089961A1 (en) * 2015-11-24 2017-06-01 Universidade De Trás-Os-Montes E Alto Douro Process for preparing cereal flours enriched with l-theanine and corresponding products
CN105434459A (en) * 2015-12-25 2016-03-30 南阳医学高等专科学校 Formula of western medicine for treating ulcer and preparation process for western medicine
IT201800010305A1 (en) 2018-11-13 2020-05-13 Danilo Ciciulla PROCEDURE FOR THE PREPARATION OF WHEAT-BASED FOODS INTENDED FOR CELIACS OR SUBJECTS WITH GLUTEN SENSITIVITY

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
EP0278174A2 (en) * 1986-12-24 1988-08-17 Glaxo Group Limited Use of fluticasone propionate in the preparation of a pharmaceutical composition for the treatment of bowel diseases
DD262999A1 (en) * 1987-07-27 1988-12-21 Adw Ddr METHOD FOR PRODUCING A DIETETIC FOR ZOELIAKIE AND SPRUCE BARRIER
SU1581315A1 (en) * 1987-12-07 1990-07-30 Пятигорский научно-исследовательский институт курортологии и физиотерапии Method of treating celiac disease of children
EP0444829A2 (en) * 1990-02-27 1991-09-04 FISONS plc Immunosuppressive compounds
WO1992018524A1 (en) * 1991-04-17 1992-10-29 Prodotti Chimici E Alimentari S.P.A. N-alkyl-tauroursodeoxycholic acids and their therapeutically active derivatives, a process for their preparation and pharmaceutical compositions containing them
WO1998003872A2 (en) * 1996-07-18 1998-01-29 Detlef Schuppan Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
EP0278174A2 (en) * 1986-12-24 1988-08-17 Glaxo Group Limited Use of fluticasone propionate in the preparation of a pharmaceutical composition for the treatment of bowel diseases
DD262999A1 (en) * 1987-07-27 1988-12-21 Adw Ddr METHOD FOR PRODUCING A DIETETIC FOR ZOELIAKIE AND SPRUCE BARRIER
SU1581315A1 (en) * 1987-12-07 1990-07-30 Пятигорский научно-исследовательский институт курортологии и физиотерапии Method of treating celiac disease of children
EP0444829A2 (en) * 1990-02-27 1991-09-04 FISONS plc Immunosuppressive compounds
WO1992018524A1 (en) * 1991-04-17 1992-10-29 Prodotti Chimici E Alimentari S.P.A. N-alkyl-tauroursodeoxycholic acids and their therapeutically active derivatives, a process for their preparation and pharmaceutical compositions containing them
WO1998003872A2 (en) * 1996-07-18 1998-01-29 Detlef Schuppan Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg), use of ttg for diagnostic purposes and therapy control, and oral pharmaceutical agent containing ttg

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BRUCE, S. E. ET AL: "Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and celiac disease", CLIN. SCI. (1985), 68(5), 573-9 CODEN: CSCIAE;ISSN: 0143-5221, XP002085949 *
DATABASE WPI Section Ch Week 199113, Derwent World Patents Index; Class B06, AN 1991-092939, XP002118955 *
DE MAGALHAES A.F.N. ET AL: "[The use of antibiotics in digestive tract diseases]. USO DE ANTIBIOTICOS EM DOENCAS DO APARELHO DIGESTIVO.", REVISTA BRASILEIRA DE CLINICA E TERAPEUTICA, (1979) 8/11 (505-516). CODEN: RBCTAP, XP002118952 *
FREEMAN H.J.: "Ranitidine -associated interstitial nephritis in a patient with celiac sprue.", CAN. J. GASTROENTEROL., (1988) 2/1 (35-36). ISSN: 0835-7900 CODEN: CJGAEJ, Canada, XP002085955 *
FRIIS S U: "COELIAC DISEASE. PATHOGENESIS AND CLINICAL ASPECTS", APMIS, vol. 104, no. SUPPL. 61, 1 January 1996 (1996-01-01), pages 5 - 48, XP000605982, ISSN: 0903-4641 *
GRAHAM D Y ET AL: "Mechanism of increase in steatorrhea with calcium and magnesium in exocrine pancreatic insufficiency: an animal model.", GASTROENTEROLOGY, (1982 SEP) 83 (3) 638-44. JOURNAL CODE: FH3. ISSN: 0016-5085., United States, XP002085956 *
GRAHAM D Y: "Pancreatic enzyme replacement: the effect of antacids or cimetidine.", DIGESTIVE DISEASES AND SCIENCES, (1982 JUN) 27 (6) 485-90. JOURNAL CODE: EAD. ISSN: 0163-2116., United States, XP002085957 *
JOURET A. ET AL: "[Digestive pathologies and intraepithelial lymphocytes]. PATHOLOGIE DIGESTIVE ET LYMPHOCYTES INTRA-EPITHELIAUX.", ACTA ENDOSCOPICA, (1995) 25/5 SUPPL. (563-569). ISSN: 0240-642X CODEN: AENDD5, France, XP002085954 *
KASPER H ET AL: "[Therapy of diseases of the small intestine]. Die Therapie von Dunndarmerkrankungen.", MEDIZINISCHE WELT, (1969 DEC 20) 51 2777-9. JOURNAL CODE: MIM. ISSN: 0025-8512., GERMANY, WEST: Germany, Federal Republic of, XP002085953 *
MEHTA D.I. ET AL: "Chronic diarrhea: Causes, presentation, and management.", INDIAN JOURNAL OF PEDIATRICS, (1996) 63/4 (459-471). ISSN: 0019-5456 CODEN: IJPEA2, India, XP002085951 *
MOLBERG, OYBIND ET AL: "Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease", NAT. MED. (N. Y.) (1998), 4(6), 713-717 CODEN: NAMEFI;ISSN: 1078-8956, XP002085952 *
SOLLID L M ET AL: "Autoantibodies in coeliac disease: tissue transglutaminase --guilt by association?.", GUT, (1997 DEC) 41 (6) 851-2., XP002118953 *
UHLIG, H. ET AL: "Role of tissue transglutaminase in gliadin binding to reticular extracellular matrix and relation to coeliac disease autoantibodies", AUTOIMMUNITY (1998), 28(4), 185-195, XP002118954 *
UNSWORTH J ET AL: "Flat small intestinal mucosa and autoantibodies against the gut epithelium.", JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, (1982) 1 (4) 503-13. JOURNAL CODE: JL6. ISSN: 0277-2116., United States, XP002085950 *

Also Published As

Publication number Publication date
AU3596199A (en) 1999-11-23
WO1999056698A2 (en) 1999-11-11
EP1075267A2 (en) 2001-02-14

Similar Documents

Publication Publication Date Title
WO1999056698A3 (en) Treatment of celiac disease
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
WO2007079202A3 (en) Treatment for acute lymhoblastic leukemia
WO2003053346A3 (en) Systems and methods for treating patients with processed lipoaspirate cells
CA2514036A1 (en) Catheter design that facilitates positioning at tissue to be diagnosed or treated
SG161259A1 (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2007100622A3 (en) Variably crosslinked tissue
EP1693073A3 (en) Wound dressings comprising hydrated hydrogels and enzymes
WO2007079169A3 (en) Treatment for acute myeloid leukemia
DE50002450D1 (en) ENZYMES FOR TREATING DIABETES MELLITUS TYPE I
WO2001066553A3 (en) Novel aryl fructose-1,6-bisphosphatase inhibitors
MXPA02007099A (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging.
WO2005048926A3 (en) Methods for treating pain
TR199802441A2 (en) Method and composition for the treatment and prevention of excessive uric acid in the blood.
WO2003045910A3 (en) Diagnosis of endothelial dysfunction by nitric oxide bioactivity index
WO2006104870A3 (en) Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
IL186356A0 (en) Method of treating of preventing type-2 diabetes
WO2022008971A3 (en) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2006025995A3 (en) Compositions and methods using md-2 mutants and chimeric proteins
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
EP1506785A4 (en) Composition for treating or preventing hyperuricemia
EP1804789A4 (en) Method of treating human preeclampsia employing resibufagenin
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2003101284A3 (en) Methods of diagnosing and treating diabetes and insulin resistance
WO2000039290A8 (en) Pharmaceutical formulation containing a microbial enzyme which digests hyaluronic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09705743

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999917810

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999917810

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999917810

Country of ref document: EP